Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.
Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.
Cancer Epidemiol Biomarkers Prev. 2023 Jan 9;32(1):12-21. doi: 10.1158/1055-9965.EPI-22-0500.
There is mixed evidence about the relations of current versus past cancer with severe COVID-19 outcomes and how they vary by patient and cancer characteristics.
Electronic health record data of 104,590 adult hospitalized patients with COVID-19 were obtained from 21 United States health systems from February 2020 through September 2021. In-hospital mortality and ICU admission were predicted from current and past cancer diagnoses. Moderation by patient characteristics, vaccination status, cancer type, and year of the pandemic was examined.
6.8% of the patients had current (n = 7,141) and 6.5% had past (n = 6,749) cancer diagnoses. Current cancer predicted both severe outcomes but past cancer did not; adjusted odds ratios (aOR) for mortality were 1.58 [95% confidence interval (CI), 1.46-1.70] and 1.04 (95% CI, 0.96-1.13), respectively. Mortality rates decreased over the pandemic but the incremental risk of current cancer persisted, with the increment being larger among younger vs. older patients. Prior COVID-19 vaccination reduced mortality generally and among those with current cancer (aOR, 0.69; 95% CI, 0.53-0.90).
Current cancer, especially among younger patients, posed a substantially increased risk for death and ICU admission among patients with COVID-19; prior COVID-19 vaccination mitigated the risk associated with current cancer. Past history of cancer was not associated with higher risks for severe COVID-19 outcomes for most cancer types.
This study clarifies the characteristics that modify the risk associated with cancer on severe COVID-19 outcomes across the first 20 months of the COVID-19 pandemic. See related commentary by Egan et al., p. 3.
目前关于现患癌症与严重 COVID-19 结局的关系以及这些关系如何因患者和癌症特征而异的证据相互矛盾。
从 2020 年 2 月至 2021 年 9 月,从 21 个美国卫生系统获取了 104590 名患有 COVID-19 的成年住院患者的电子健康记录数据。从当前和过去的癌症诊断预测住院死亡率和 ICU 入院率。检查了患者特征、疫苗接种状态、癌症类型和大流行年份的调节作用。
患者中有 6.8%(n=7141)为现患癌症,6.5%(n=6749)为既往癌症。现患癌症预测了两种严重结局,但既往癌症没有;死亡率的调整比值比(aOR)分别为 1.58(95%置信区间[CI],1.46-1.70)和 1.04(95% CI,0.96-1.13)。大流行期间死亡率有所下降,但现患癌症的增量风险持续存在,且在年轻患者中比老年患者中更大。既往 COVID-19 疫苗接种总体上降低了死亡率,并且在现患癌症患者中也降低了死亡率(aOR,0.69;95% CI,0.53-0.90)。
现患癌症,尤其是在年轻患者中,使 COVID-19 患者的死亡和 ICU 入院风险显著增加;既往 COVID-19 疫苗接种降低了与现患癌症相关的风险。对于大多数癌症类型,既往癌症史与严重 COVID-19 结局的风险增加无关。
本研究阐明了在 COVID-19 大流行的头 20 个月中,与癌症相关的严重 COVID-19 结局风险的特征。见 Egan 等人的相关评论,第 3 页。